Selpercatinib is indicated for patients with advanced RET-mutant MTC as first-line or progressing to vandetanib or cabozantinib, reaching durable responses with lower side effects compared to these MKI [53, 75]. Here, RET is linked to medullary thyroid gland carcinoma.